A phase I, open-label, two-part study to assess the absolute bioavailability and Mass Balance of Navoximod, a Novel Ido1 Inhibitor, in Healthy Subjects
Latest Information Update: 16 Apr 2019
At a glance
Most Recent Events
- 11 Apr 2019 Results published in the British Journal of Clinical Pharmacology
- 27 Mar 2018 New trial record
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics